FinnGen researchers present at the ASHG 2022

Results based on the FinnGen data are presented in 30 talks or posters during the 2022 Annual Meeting of the American Society of Human Genetics (ASHG) in Los Angeles, October 25-29. Come and meet our researchers!
ASHG Annual Meeting 2022 and FinnGen logos.

Tuesday Oct 25

Poster talks II

7:48pm - 7:51pm

Conv Ctr/Petree D/West Building

ProgNbr 642 / P: Sanni Ruotsalainen - Phenome and genomewide recessive scan of coding variants reveals novel associations for female infertility


Wednesday Oct 26

Platform - Applying Mendelian randomization to complex traits


8:45am - 9:00am

Conv Ctr/West Hall A/West Building

ProgNbr 073: Denis Baird - Mendelian randomization and colocalization characterize the impact of the plasma proteome on human complex diseases


Platform - Considering ancestry in study populations

9:00am - 9:15am

Conv Ctr/Room 515/West Building

ProgNbr 082: Juulia Partanen - Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics


Platform - Let's talk about sex and its contributions to disease risk

10:45am - 11:00am

Conv Ctr/Concourse Hall F/West Building 

ProgNbr 136: Jermy Bradley - Testing for interaction using over 1 million individuals and 20 diseases shows considerable differences in polygenic risk score estimates across age groups and sexes


Platform - Somatic mosaicism in human health and disease

11:15am - 11:30am

Conv Ctr/Petree C/West Building

ProgNbr 162: Aoxing Liu - Genetic investigation of mosaic loss of the X chromosome in peripheral leukocytes of 918,085 women identifies germline predisposition and strong signals of haplotype selection


Poster session 3:00pm - 4:45pm 

Cancer Posters

PB1116: Anil Kumar - Genome-wide association study identifies 4 novel risk loci including a missense variant in LGR5 for small intestinal neuroendocrine tumors

PB1138 Nina Mars - Impact of polygenic risk, pathogenic variants, and family history on detection of breast cancers within and outside the national mammography screening programme on 117,252 women over 1992-2019


Complex Traits Posters

PB1246: Andrea Ganna - A nationwide approach to understand the role of health, socioeconomic and genetic information in predicting COVID-19 vaccination uptake

PB1358: Amy Hart - Evaluation of genetic support for targeting the IL-23 pathway: current and future therapeutic opportunities

PB1388: Tommi Strausz - Genetic analysis of bruxism and its associations to sleep, psychiatric and behavioural traits

PB1394: Joel Rämö - Genetic characterization of central serous chorioretinopathy and pleiotropic effects with age-related macular degeneration

PB1623: Satu Strausz - Secretoglobin family 1D member 2 (SCGB1D2) protein inhibits growth of Borrelia burgdorferi and affects susceptibility to Lyme disease

PB1661: Jaakko Tyrmi - The first GWAS on intrahepatic cholestasis of pregnancy unveils novel bile acid metabolism related associations


Prenatal, Perinatal, and Developmental Genetics Posters

PB2108: Sanni Ruotsalainen - Phenome and genomewide recessive scan of coding variants reveals novel associations for female infertility


Molecular Effects of Genetic Variation Posters

PB2543: Josh Chiou - Comprehensive signal identification highlights the contribution of protein QTLs to complex trait genetics

PB2674: Clara Benoit-Pilven - Population-specific RNA-seq data empowers the functional follow-up of disease-associations from FinnGen


Statistical Genetics and Genetic Epidemiology Posters

PB3268: Lisa Eick - A machine-learning approach for disease prediction improves GWAS and polygenic scores

PB3569: Jiwoo Lee - Quantifying the causal impact of modifiable risk factors and biomarkers on total healthcare burden via Mendelian randomization


Thursday Oct 27

Platform - Using EHRs to withdraw new insights from biobanks

1:45pm - 2:00pm

Conv Ctr/Concourse Hall E/West Building 

ProgNbr 326: Brooke Wolford - Variability in lifetime risk of 20 complex diseases across European countries and polygenic score strata in over 1 million individuals


Poster session 3:00pm - 4:45pm 

Complex Traits Posters

PB1232: Tuomo Kiiskinen - A catalog of genetic predictors impacting lifelong medication use patterns in hyperlipidemia, hypertension and type 2 diabetes

PB1373: Heidi Hautakangas - Fine-mapping 110 migraine risk loci using 98,375 migraine cases

PB1443: Mart Kals - Genome-wide meta-analysis identifies novel susceptibility loci for acne vulgaris

PB1573: Annina Preussner - Phenome-wide perspective into the role of Finnish Y chromosome variation in complex diseases


Statistical Genetics and Genetic Epidemiology Posters

PB3300: Anniina Tervi - Alpha-2A adrenergic receptor (ADRA2A) modulates susceptibility to Raynaud’s disease

PB3395: Mattia Cordioli - Exploring the genetic, socio-economic and environmental determinants of drug adherence


Friday Oct 28

Platform - Extended applications of polygenic risk scores

10:45am - 11:00am 

Conv Ctr/Concourse Hall E/West Building 

ProgNbr 387: Nina Mars - Can genetic associations for disease onset be used to predict disease prognosis? The glass is half empty


Platform - Towards the defeat of neurodegenerative disease

10:45am - 11:00am 

Conv Ctr/Petree D/West Building

ProgNbr 427: Joni Lindbohm - Immune system and blood-brain barrier-wide biomarker analyses provide causal evidence for autoimmunity in dementia causing diseases


Platform - Genetics and integrated -omics of diabetes and associated metabolic disorders

11:00am - 11:15am 

Conv Ctr/Room 515/West Building

ProgNbr 396: Xianyong Yin - Integrating transcriptomics, metabolomics, and GWAS helps reveal molecular mechanisms for metabolite levels and disease risk


11:30am - 11:45am 

Conv Ctr/Room 515/West Building

ProgNbr 396: Amanda Elliott - New common genetic loci for gestational diabetes mellitus reveal a distinct genetic architecture from type 2 diabetes mellitus


Saturday Oct 29


Platform - The many ways to make polygenic risk scores

9:45am - 10:00am 

Conv Ctr/Concourse Hall E/West Building 

ProgNbr 561: Julian Wanner - Potential clinical utility of polygenic risk scores in disease prognosis. The glass is half full